Neumora Therapeutics, Inc. (NMRA): Results of Operations and Financial Condition
Neumora Therapeutics, Inc. (NMRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nmra-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by
How this was made
The 30-second read
Why it matters
Traders can update models for cash burn and catalyst timing, and reassess execution risk following the CEO transition and CMO appointment.
Market read
Primary disclosure of cash position, net loss, and multiple 2026 clinical milestones, plus CEO/CMO appointments, which can drive near-term biotech valuation and trading volatility.
What to watch
The cash runway is into Q3 2027, but the article does not quantify expected incremental funding needs beyond that window or any probability-weighted milestone success, which can drive valuation sensitivity.
Background
SEC Form 8-K Item 2.02 and 5.02 includes Q2 2026 financial results, cash runway guidance, pipeline milestone timing, and leadership changes (CEO/Executive Chair and CMO appointment).
Ticker impact
Neumora reports Q2 2026 results, $116.8M cash runway into Q3 2027, and updates clinical timelines for NMRA-215, NMRA-511, and NMRA-898.
Moderate positive bias into the next catalyst windows (IND submission and Phase 1/2 readouts), with volatility tied to clinical execution and cash burn.
This is a primary 8-K with financial datapoints and specific development timing (IND in Q4 2026; data readouts in Q4 2026 and H2 2026) plus leadership appointments, which markets typically reprice for biotech execution and runway.
Market effects
Adds another clinical-stage neuroscience biotech datapoint, reinforcing investor focus on cash runway and milestone cadence rather than near-term profitability.
Limited, company-specific impact; no broader regional macro or policy linkage stated.
Primarily US-listed biotech sentiment; no international regulatory or partnership terms disclosed.
Counterpoint
Milestone timing is still forward-looking and execution risk remains high for Phase 1/2 programs, so the runway may only delay dilution concerns rather than remove them.
Key entities
- issuerNeumora Therapeutics, Inc.
Clinical-stage biopharmaceutical company filing Q2 2026 results and providing pipeline and leadership updates.
- executiveJoshua Pinto, Ph.D.
Appointed President and Chief Executive Officer, and member of the Board of Directors.
- executivePaul L. Berns
Co-founder appointed Executive Chair after stepping from CEO role.
- executiveDoron Sagman, M.D.
Appointed Chief Medical Officer.
- pipeline_programNMRA-215
NLRP3 inhibitor targeting obesity and cardiometabolic disease; IND planned for Q4 2026 and Phase 1 initiation by end of 2026.
